2019
DOI: 10.1038/s41587-019-0203-2
|View full text |Cite
|
Sign up to set email alerts
|

Large dataset enables prediction of repair after CRISPR–Cas9 editing in primary T cells

Abstract: Competing interests A.M. is a co-founder of Spotlight Therapeutics. A.M. has served as an advisor to Juno Therapeutics and is a member of the scientific advisory board at PACT Pharma and an advisor to Sonoma Biotherapeutics. The Marson laboratory has received sponsored research support from Juno Therapeutics, Epinomics, Sanofi and a gift from Gilead. A.M. and T.L.R. are co-founders of Arsenal Biosciences and T.L.R. is chief scientific officer of the company. Data availability All the raw data and analyses are … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

6
109
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 96 publications
(117 citation statements)
references
References 19 publications
6
109
0
Order By: Relevance
“…We will also assess if the removal of the two gRNA target sites from the donor plasmid would facilitate HDR-based gene insertion in rice. It would also be informative to determine whether certain gRNAs can facilitate large DNA insertions during the DNA-repair process as has been demonstrated for human primary T cells 52 .…”
Section: Discussionmentioning
confidence: 99%
“…We will also assess if the removal of the two gRNA target sites from the donor plasmid would facilitate HDR-based gene insertion in rice. It would also be informative to determine whether certain gRNAs can facilitate large DNA insertions during the DNA-repair process as has been demonstrated for human primary T cells 52 .…”
Section: Discussionmentioning
confidence: 99%
“…Third, indel mutations formed at DSB sites generated by Cas nucleases in CRISPRmediated HDR experiments can result in defective PCR amplification of indel-containing loci that have not undergone HDR and therefore cause an overestimation of the frequency of HDR events by DTECT ( Figures S11A and S11B). However, given that the mutagenic spectrum of indel mutations induced by any sgRNA is predictable (Allen et al, 2019;Leenay et al, 2019;Shen et al, 2018;van Overbeek et al, 2016; inDelphi, https://indelphi.giffordlab.mit.edu/), the negative impact of indel mutations on DTECT-based quantification of CRISPR-mediated HDR events can be avoided by introducing the desired genomic changes in indel-free regions adjacent to CRISPR-induced cut sites ( Figures S11C and S11D). This limitation does not affect the detection of CRISPR-mediated base editing and prime editing events or naturally occurring genetic variants, which are accompanied by either very low frequency (Anzalone et al, 2019;Gaudelli et al, 2017;Komor et al, 2017;Yeh et al, 2018) or absence of DSB-induced indel formation, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…However, the efficiency of conversion of different pGuides varied and appeared to depend upon both the spacer 18 sequence and the stem sequence. Nucleotide composition is known to greatly influence DNA repair outcomes at spCas9 generated DSBs (Allen et al, 2018;Chakrabarti et al, 2019;Leenay et al, 2019;Shen et al, 2018;van Overbeek et al, 2016). It is possible that some stem sequences are less amenable to the desired MMEJ repair event if cryptic microhomologies occur because of the nucleotide composition of the spacer region or between the target site in the stem and the ribozyme DNA sequence.…”
Section: Discussionmentioning
confidence: 99%